| Liu, Liang |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT03950154: Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 198 | RoW | Bevacizumab Injection [Avastin], Avastin, Oxaliplatin, Capecitabine, PD1-T cells, PD-1 monoclonal antibody-activated peripheral blood T-lymphocyte | Tianjin Medical University Cancer Institute and Hospital | Colorectal Cancer | 08/23 | 08/23 | | |
NCT06704620: Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 430 | RoW | Diphenhydramine, Tislelizumab, Pemetrexed, Albumin paclitaxel, Carboplatin, Cisplatin | Tianjin Medical University Cancer Institute and Hospital | Advanced and Metastatic NSCLC | 11/26 | 11/27 | | |
CCICC-002b, NCT04836728: Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer |
|
|
| Not yet recruiting | 2 | 156 | RoW | CIK cell injection, Autologous cytokine-induced killer cells, Sintilimab Injection, PD-1 inhibitor, Pemetrexed, Pemetrexed injection, Albumin paclitaxel, Albumin paclitaxel Injection, Carboplatin, Carboplatin injection | Tianjin Medical University Cancer Institute and Hospital | Non-small Cell Lung Cancer Metastatic, First-line Treatment | 06/22 | 12/23 | | |
NCT05507606: Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations |
|
|
| Recruiting | 2 | 50 | RoW | Osimertinib, EGFR-TKI, Bevacizumab Biosimilar IBI305, Anti-angiogenesis, Carboplatin, Chemotherapy, Pemetrexed | Tianjin Medical University Cancer Institute and Hospital | Non Small Cell Lung Cancer | 08/23 | 08/24 | | |
NCT06166589: Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 19 | RoW | Zimberelimab, Oxaliplatin, S-1, Irinotecan | Shanghai Zhongshan Hospital | Previously AG Chemotherapy Treated Pancreatic Cancer | 01/26 | 01/27 | | |
NCT05562297: Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | sintilimab, Tyvyt, nab-paclitaxel, Abraxane, gemcitabine, GEMZAR | Shanghai Zhongshan Hospital, Fudan University | Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB, Pancreatic Cancer Stage III | 10/25 | 10/26 | | |
NCT05507593: Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 18 | RoW | DLL3-CAR-NK cells | Tianjin Medical University Cancer Institute and Hospital | SCLC, Extensive Stage | 03/23 | 07/23 | | |
| Not yet recruiting | N/A | 60 | RoW | Endostar, S1 | Peking University Third Hospital, Mianyang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Peking University International Hospital, China-Japan Friendship Hospital, The fifth medical center of PLA general hospital, Second Hospital of Shanxi Medical University, Hiser Medical Center of Qingdao, Guangxi Ruikang Hospital, GEM flower hospital of Liaohe oil field, Tang-Du Hospital, Third Affiliated Hospital of Guizhou Medical University, Liuzhou Worker's Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian municipal central hospital affiliated of dalian medical university | Radiotherapy Side Effect | 01/22 | 01/23 | | |
| Recruiting | N/A | 1500 | RoW | PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs | Tianjin Medical University Cancer Institute and Hospital | Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia, Serum Ferritin | 07/26 | 07/27 | | |
| Cao, Leiming |
NCT06259526: A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression |
|
|
| Recruiting | 2 | 260 | RoW | Placebo group, JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 pills; JS1-1-01 placebo pills, JS1-1-01 high-dose group, JS1-1-01 pills; Duloxetine hydrochloride placebo capsules, Active drug group, JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule | Tasly Pharmaceutical Group Co., Ltd | Depression | 04/25 | 04/25 | | |
